Current taxane formulations and emerging cabazitaxel delivery systems

被引：0
作者：
Boyang Sun
Robert M. Straubinger
Jonathan F. Lovell
机构：
[1] State University of New York,Department of Biomedical Engineering, University at Buffalo
[2] State University of New York,Department of Chemical and Biological Engineering, University at Buffalo
[3] State University of New York,Department of Pharmaceutical Sciences, University at Buffalo
来源：
Nano Research | 2018年 / 11卷
关键词：
cabazitaxel; Jevtana; taxanes; drug delivery systems; nanocarriers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cabazitaxel is a second-generation taxane with promising anti-tumor activity and is approved for treating hormone-refractory metastatic prostate cancer previously treated with docetaxel. Although first-generation taxanes (i.e. paclitaxel and docetaxel) have sparked broad interest in a variety of drug delivery vehicles, fewer have yet been developed for cabazitaxel. This review summarizes several clinical-stage approaches for taxane formulation and recent efforts to develop novel cabazitaxel delivery systems.
引用
收藏
页码：5193 / 5218
页数：25
相关论文
共 1017 条
  • [101] Lockhart A. C.(2005)Development and characterization of a novel Cremophor® EL free liposome–based paclitaxel (LEP–ETU) formulation Eur. J. Pharm. Biopharm. 59 177-5863
  • [102] Tirona R. G.(2008)Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome–entrapped paclitaxel Clin. Cancer Res. 14 5856-1954
  • [103] Kim R. B.(2013)Bioequivalence of liposome–entrapped paclitaxel easy–to–use (LEP–ETU) formulation and paclitaxel in polyethoxylated castor oil: A randomized, two–period crossover study in patients with advanced cancer Clin. Ther. 35 1946-1036
  • [104] Childs S.(2012)Vascular and pharmacokinetic effects of EndoTAG–1 in patients with advanced cancer and liver metastasis Ann. Oncol. 23 1030-1245
  • [105] Yeh R. L.(2010)Vascular targeting by EndoTAG™–1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer Int. J. Cancer 126 1235-326
  • [106] Hui D.(2009)Paclitaxel encapsulated in cationic liposomes: A new option for neovascular targeting for the treatment of prostate cancer Oncol. Rep. 22 321-1413
  • [107] Ling V.(1998)Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice J. Clin. Invest. 101 1401-2461
  • [108] Hopper–Borge E.(2017)Vessel–targeted chemophototherapy with cationic porphyrin–phospholipid liposomes Mol. Cancer Ther. 16 2452-1222
  • [109] Chen Z. S.(2012)Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: A randomized controlled phase II trial Ann. Oncol. 23 1214-3247
  • [110] Shchaveleva I.(2007)Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation Mol. Cancer Ther. 6 3239-622
6789101112131415